Navigation Links
Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
Date:12/6/2012

HOLLYWOOD, Fla. and EVANSTON, Ill., Dec. 6, 2012 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.  GLYX-13 is a novel partial agonist of the NMDA receptor.  The Phase Ila results are being presented this week at the 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

The Phase IIa results show that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with one or more antidepressant agents.  The reductions were evident within 24 hours and persisted for an average of seven days.  Importantly, the effect size, a measure of the magnitude of the drug's antidepressant efficacy, observed at 24 hours and at seven days after a single administration of GLYX-13, was nearly double the effect size seen with most other antidepressant drugs after 4-6 weeks of repeated dosing.

In the Phase IIa trial, GLYX-13 was well tolerated.  Reported side effects were mild to moderate and were consistent with those observed in subjects receiving placebo.  Consistent with previous studies, GLYX-13 did not produce any of the schizophrenia-like psychotomimetic effects associated with other drugs that modulate the NMDA receptor.

"These data are an important step in validating Naurex's mission of developing breakthrough therapies for depression and other CNS disorders," said Derek Small, CEO of Naurex.  "Our founder discovered a new class of drugs that appeared to have the remarkable antidepressant efficacy of ketamine-like compounds, but without their limiting side effects.  These Phase II results suggest that this discovery may translate into measurable health improvements for individuals with depression, which
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
8. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
9. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Research and Markets  has announced ... (Biodegradable Polymer, Food & Beverage, Personal Care & ... report to their offering. Lactic ... asymmetrical carbon atom. The main applications of lactic ... beverage, personal care product, and pharmaceutical industries. ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... Research and Markets  has announced the addition of ... Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... spectrometer industry. The report provides a basic ... industry chain structure. The isotope ratio mass spectrometer market ...
(Date:8/27/2014)... 2014 BIOEQUA, an innovative line of ... of a handheld spray, has made its EQUA ESSENTIAL ... , The brand began with an unexpected discovery in ... to learn that the application of nanospray technology allowed ... delivered directly to skin's basal layer. This resulted in ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2
... - Automated Benchtop Workstation Aids Mass Spectrometer Analysis ... Life,Sciences, Inc. (Nasdaq: CALP ) today announced ... solution designed to automate Solid,Phase Extraction (SPE). With ... software interface, the Zephyr SPE Workstation is,designed to ...
... the, laparoscopic advanced energy market was worth over ... Dec. 11 Millennium Research Group,s US,Laparoscopic Marketrack(TM) ... advanced,energy market, which includes open and laparoscopic devices, ... demand for advanced energy instruments,from young physicians, these ...
... TB-402 Shows Clear Promise as a Stable Long-acting ... NV (Euronext Brussels:THR), a biotechnology company,focused on vascular ... the,first Phase I trial of TB-402 were presented ... 49th Annual Meeting in Atlanta,Georgia, USA. TB-402 is ...
Cached Biology Technology:Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction 2Young Physicians Demanding Advanced Laparoscopic Energy Instruments 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4
(Date:8/27/2014)... to listen carefully to someone, the first thing we ... is stop moving altogether. This strategy helps us hear ... movements. , This interplay between movement and hearing also ... evidence has long suggested that the brain,s motor cortex, ... gives rise to our conscious perception of sound. , ...
(Date:8/27/2014)... German . ... inherited disease affecting the peripheral nervous system. Researchers from ... of Experimental Medicine and University Medical Centre Gttingen have ... in rats with the disease. These cells enwrap the ... which facilitates the rapid transfer of electrical impulses. If ...
(Date:8/27/2014)... each year in U.S. waters and become what are ... crabs, and other species such as turtles. These traps ... who depend on the resources--losses that are largely preventable, ... report, published in the Marine Pollution Bulletin , ... derelict fish trap problem, and so-called "ghost fishing," nationally, ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Potential therapy for incurable Charcot-Marie-Tooth disease 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... been amazed by the power of gecko feet, which let ... carrying nine pounds up a wall without slipping. Now, a ... of Massachusetts Amherst have discovered exactly how the gecko does ... hold 700 pounds on a smooth wall. Doctoral candidate ...
... single most common cause of congestive heart failure and sudden ... of people throughout Central and South America. But as global ... States and Europe as well. Chagas, which is ... T. cruzi , is the leading cause of death among ...
... world,s top conferences in human-computer interaction, TEI 2012, is ... world are coming to Kingston to present the latest ... the technology on display includes: a two-sided flexible TV ... yoga mats; a glove for deaf-blind people that translates ...
Cached Biology News:Inspired by gecko feet, UMass Amherst scientists invent super-adhesive material 2UGA animal vaccine may slow deadly spread of Chagas disease 2UGA animal vaccine may slow deadly spread of Chagas disease 3
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
... normal paraffin tissue array is designed ... of interest in extensive panels of ... brain, heart, kidney, liver, lung, muscle, ... on positively charged glass slide. ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
Biology Products: